The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Cystatin C as a Risk Factor for Outcomes in Chronic Kidney Disease
Abstract
BACKGROUND: No study has compared cystatin C level, serum creatinine concentration, and estimated glomerular filtration rate (GFR) as risk factors for outcomes in chronic kidney disease (CKD), and none has compared measured GFR with CKD in any population. OBJECTIVE: To compare cystatin C level with serum creatinine concentration and iothalamate GFR as risk factors for death and kidney failure. DESIGN: Observational study using serum cystatin C assayed from baseline samples of the Modification of Diet in Renal Disease Study (1989-1993). SETTING: 15 clinical centers in the United States that participated in the Modification of Diet in Renal Disease Study. PARTICIPANTS: 825 trial participants with stage 3 or 4 nondiabetic CKD who had measurements of serum cystatin C. MEASUREMENTS: All-cause mortality, cardiovascular (CVD) mortality, and kidney failure until December 2000. RESULTS: Mean cystatin C level, creatinine concentration, and GFR were 2.2 mg/L (SD, 0.7), 212.16 micromol/L (SD, 88.4) (2.4 mg/dL [SD, 1.0]), and 33 mL/min per 1.73 m2 (SD, 12), respectively. Median follow-up was 10 years. Twenty-five percent of patients (n = 203) died of any cause, 15% (n = 123) died of CVD, and 66% (n = 548) reached kidney failure. In multivariate-adjusted models, 1-SD decreases in 1/creatinine, GFR, and 1/cystatin C were associated with increased risks for all-cause mortality of 1.27 (95% CI, 1.06 to 1.49), 1.27 (CI, 1.08 to 1.49), and 1.41 (CI, 1.18 to 1.67), respectively. For CVD mortality, the increased risks were 1.32 (CI, 1.05 to 1.64), 1.28 (CI, 1.04 to 1.59), and 1.64 (CI, 1.28 to 2.08), respectively. For kidney failure, the increased risks were 2.81 (CI, 2.48 to 3.18), 2.41 (CI, 2.15 to 2.70), and 2.36 (CI, 2.10 to 2.66), respectively. LIMITATION: The Modification of Diet in Renal Disease Study cohort may not be representative of all patients with nondiabetic CKD because participants were more likely to reach kidney failure than death in follow-up. CONCLUSION: The association of cystatin C level with all-cause and CVD mortality was as strong as or perhaps stronger than that of iothalamate GFR with these outcomes in stage 3 or 4 CKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Self-citationChronic kidney disease and the risks of death, cardiovascular events, and hospitalization
Go, A. S., Chertow, G. M., Fan, D., McCulloch, C. E., & Hsu, C.-Y. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041031 · Cited by 11,369
Cited by
Klotho Deficiency Causes Vascular Calcification in Chronic Kidney Disease
Hu, M. C., Shi, M., Zhang, J., Quiñones, H., Griffith, C., Kuro-o, M., & Moe, O. W. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009121311 · Cited by 926
Fatty Kidney, Hypertension, and Chronic Kidney Disease: The Framingham Heart Study
Foster, M. C., Hwang, S.-J., Porter, S. A., Massaro, J. M., Hoffmann, U., & Fox, C. S. (2011) · Hypertension · doi:10.1161/hypertensionaha.111.175315 · Cited by 356
Biochemical and Clinical Impact of Organic Uremic Retention Solutes: A Comprehensive Update
Vanholder, R., Pletinck, A., Schepers, E., & Glorieux, G. (2018) · Toxins · doi:10.3390/toxins10010033 · Cited by 356
Update on Cystatin C: Incorporation Into Clinical Practice
Shlipak, M. G., Mattes, M. D., & Peralta, C. A. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2013.03.027 · Cited by 283
Self-citationKidney and eye diseases: Common risk factors, etiological mechanisms, and pathways
Wong, C. W., Wong, T. Y., Cheng, C.-Y., & Sabanayagam, C. (2014) · Kidney International · doi:10.1038/ki.2013.491 · Cited by 276
Metadata
- Authors
- Menon, V., Shlipak, M. G., Wang, X., Coresh, J., Greene, T., Stevens, L., Kusek, J. W., Beck, G. J., Collins, A. J., Levey, A. S., & Sarnak, M. J.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2007-07-03
- Volume
- 147
- Issue
- 1
- Pages
- 19-27
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2125327064
- Cited by
- 204
- References
- 2
- FWCI
- 10.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cystatin C as a Risk Factor for Outcomes in Chronic Kidney Disease. https://app.cochat.ai/papers/10.7326/0003-4819-147-1-200707030-00004
- The paper
- Menon, V., Shlipak, M. G., Wang, X., Coresh, J., Greene, T., Stevens, L., Kusek, J. W., Beck, G. J., Collins, A. J., Levey, A. S., & Sarnak, M. J. (2007). Cystatin C as a Risk Factor for Outcomes in Chronic Kidney Disease. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-147-1-200707030-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.